April 28, 2022
On behalf of our investors in the Private Debt IV – Flexible fund, we are pleased to have supported Procuritas with the financing of Nordic Biomarker, a leading Swedish developer and manufacturer of reagents used for blood coagulation testing.
About Nordic Biomarker
Founded in 2007, Nordic Biomarker is a developer and manufacturer of advanced reagents, calibrators and controls for lab-based blood coagulation testing, based in Umeå, Sweden. The company offers products used for a wide range of routine and specialty lab-based tests across patients’ treatment journey. Product development and production is performed in-house at Nordic Biomarker’s facilities in Sweden and distributed to end-customers via a network of distributors.
With a growing product portfolio of both routine and specialty reagents for the blood coagulation testing, Nordic Biomarker is a valued collaboration partner for its customers, supplying the healthcare sector with a high-quality product that enables precise analysis of patients’ health.
If you’d like more information on this release, please contact:
Caroline Soliman, Director
Tel: +45 3625 6144
Mikkel Sckerl, Partner
Tel: +45 35256112